GHENT, BELGIUM--(Marketwire - July 26, 2011) -
GHENT, Belgium, 26 July 2011 - Ablynx [Euronext Brussels: ABLX] today
announced
that it has been granted a Certificate of Good Laboratory Practise (GLP)
from
the Belgian Scientific Institute of Public Health (IPH) for its new GLP
unit at
its headquarters in Ghent, Belgium, after having been inspected in May
2011.
Having received this GLP certificate, Ablynx's GLP unit will be
able to
seamlessly carry out pre-clinical analytical testing and
pharmacokinetics
studies in-house, to the required regulatory standard.
Dr Edwin Moses, CEO and Chairman of Ablynx, commented: "Being awarded
the GLP
certificate from the Belgian authorities confirms our commitment to
consistently
perform at a high standard in this stringent regulatory environment. This
is an
important milestone for Ablynx as we continue to grow towards a product-
based
company. With this certificate, we no longer solely rely on third
parties to
carry out the pre-clinical GLP testing for our programmes. This enables
us to
retain more control on quality, timing and associated costs."
About Good Laboratory Practise (GLP)
Good Laboratory Practise specifically refers to a quality system of
management
controls for research laboratories and organisations to ensure the
uniformity,
consistency, reliability, reproducibility, quality, and integrity of
chemical
(including pharmaceuticals) safety and efficacy tests.
Complete version of the press release:
http://hugin.info/137912/R/1533547/467177.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ablynx via Thomson Reuters ONE
[HUG#1533547]
